What's the common thread connecting AI advances, biological breakthroughs, a preponderance of high-risk-high-reward research, escalating geopolitical tensions and a hollowed-out U.S. public health sector? - They all heighten the risk that one day a lethal human-made pathogen will emerge, either accidentally or intentionally, and we won't be ready for it. Why it matters: The same advances that make this a pivotal moment for medical innovation are intensifying the risk of catastrophic lab mishaps, though how significant a risk is hotly debated by experts. - "It is a very small tweak from trying to target a disease, and making gene therapies to try to target a disease, to turning a virus into something that can be much more detrimental,"…
Moderna's own research shows 5,000 novel jabs required to prevent one hospitalization over standard vaccine. "Pharma finished recapturing" FDA after exit of officials with higher standards, drug industry journalist says.
The Food and Drug Administration (FDA) has approved Moderna's mRNA-based seasonal flu vaccine.
The Food and Drug Administration (FDA) has granted approval for Moderna’s mRNA-based flu vaccine for adults 50 and older, despite earlier regulatory concerns. PULSE POINTS WHAT HAPPENED: The Food and Drug Administration (FDA) has approved Moderna’s mRNA-based seasonal flu vaccine . DETAIL: Named mFLUSIVA, the vaccine was approved on Wednesday. It is aimed at people aged 50 and older. The decision comes after the FDA initially declined to approve the vaccine back in February. Specifically, the vaccine was initially blocked as the clinical trial did not use the best available comparator for adults aged 65 and older. “We are grateful to the clinical trial participants, investigators, regulators and Moderna teams whose…Open
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
Ten of 12 scientists on call that produced the "Proximal Origin" paper thought that "deliberate insertion was possible," Fauci's alleged notes say in regard to COVID-19 spike protein binding to human receptors.
Tech companies are aiming for the stars as they seek permits for orbital data centers. And just like on Earth, this advancement does not come without warnings. Cole Donovan, director of science policy and advocacy for Stand Up for Science, joins NewsNation's Hena Doba to explain the issues with orbital data centers and how they could alter the atmosphere. "NewsNation Prime" is America’s source for unbiased news offering a full range of perspectives from across the U.S. Weekends starting at 7p/6C. #Prime NewsNation is your source for fact-based, unbiased news for all Americans.
An odd silence has surrounded a delay to fill several open seats on the board of the Smithsonian, even as a fierce battle to control the institution ensues.
